Steatosis and fibrosis progression in patients with recurrent hepatitis C infection: Complex interactions providing diagnostic and therapeutic challenges

Liver Transplantation

Volumn 17, Issue 12, 2011, Pages 1374-1379

  Hübscher, Stefan G ^a,b  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE ASSOCIATION; DISEASE COURSE; FATTY LIVER; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION RISK; LIVER FIBROSIS; LIVER TRANSPLANTATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECURRENCE RISK; RECURRENT VIRUS INFECTION; REVIEW;

FATTY LIVER; FEMALE; HEPATITIS C; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALE;

EID: 82455219361     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.22452     Document Type: Review

References (56)

1. Brandman D, Pingitore A, Lai JC, Roberts JP, Ferrell L, Bass NM, Terrault NA,. Hepatic steatosis at 1 year is an additional predictor of subsequent fibrosis severity in liver transplant recipients with recurrent hepatitis C virus. Liver Transpl 2011; 17: 1380- 1386.
2. Serfaty L, Capeau J,. Hepatitis C, insulin resistance and diabetes: clinical and pathogenic data. Liver Int 2009; 29 (suppl 2): 13-25.
3. Asselah T, Rubbia-Brandt L, Marcellin P, Negro F,. Steatosis in chronic hepatitis C: why does it really matter? Gut 2006; 55: 123-130. (Pubitemid 41820647)
4. Del Campo JA, Romero-Gõmez M,. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15: 5014-5019.
5. Younossi ZM, McCullough AJ,. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: impact on disease progression and treatment response. Liver Int 2009; 29 (suppl 2): 3-12.
6. Bartosch B,. Hepatitis C virus and its complex interplay with hepatic glucose and lipid metabolism. J Hepatol 2009; 50: 845-847.
7. Eslam M, Khattab MA, Harrison SA,. Insulin resistance and hepatitis C: an evolving story. Gut 2011; 60: 1139-1151.
8. Petta S, Amato M, Cabibi D, Cammà C, Di Marco V, Giordano C, et al. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology 2010; 52: 1543-1552.
9. Clément S, Negro F,. Hepatitis C virus: the viral way to fatty liver. J Hepatol 2007; 46: 985-987. (Pubitemid 46669740)
10. Kurosaki M, Matsunaga K, Hirayama I, Tanaka T, Sato M, Komatsu N, et al. The presence of steatosis and elevation of alanine aminotransferase levels are associated with fibrosis progression in chronic hepatitis C with non-response to interferon therapy. J Hepatol 2008; 48: 736-742.
11. Negro F,. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010; 59: 1279-1287.
12. Clouston AD, Powell EE, Walsh MJ, Richardson MM, Demetris AJ, Jonsson JR,. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-818. (Pubitemid 40462943)
13. Svegliati-Baroni G, Faraci G, Fabris L, Saccomanno S, Cadamuro M, Pierantonelli I, et al. Insulin resistance and necroinflammation drives ductular reaction and epithelial-mesenchymal transition in chronic hepatitis C. Gut 2011; 60: 108-115.
14. Dai CY, Huang JF, Hsieh MY, Hou NJ, Lin ZY, Chen SC, et al. Insulin resistance predicts response to peginterferon-alpha/ribavirin combination therapy in chronic hepatitis C patients. J Hepatol 2009; 50: 712-718.
15. Poustchi H, Negro F, Hui J, Cua IH, Brandt LR, Kench JG, George J,. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008; 48: 28-34. (Pubitemid 350191982)
16. Arase Y, Suzuki F, Suzuki Y, Akuta N, Kobayashi M, Kawamura Y, et al. Sustained virological response reduces incidence of onset of type 2 diabetes in chronic hepatitis C. Hepatology 2009; 49: 739-744.
17. Roche B, Samuel D,. Risk factors for hepatitis C recurrence after liver transplantation. J Viral Hepat 2007; 14 (suppl 1): 89-96. (Pubitemid 47624117)
18. Roche B, Samuel D,. Hepatitis C virus: up to the minute. Liver Transpl 2010; 16 (suppl 2): S26-S35.
19. Hubscher SG, Clouston AD,. Transplantation pathology. In:, Burt AD, Portmann BC, Ferrell LD, eds. MacSween's Pathology of the Liver. 6th ed. Edinburgh, United Kingdom: Churchill Livingstone. In press.
20. Chen T, Jia H, Li J, Chen X, Zhou H, Tian H,. New onset diabetes mellitus after liver transplantation and hepatitis C virus infection: meta-analysis of clinical studies. Transpl Int 2009; 22: 408-415.
21. Pageaux GP, Faure S, Bouyabrine H, Bismuth M, Assenat E,. Long-term outcomes of liver transplantation: diabetes mellitus. Liver Transpl 2009; 15 (suppl 2): S79-S82.
22. Audimoolam VK, Foxton MR, Agarwal K, O'Grady JG, Heneghan MA,. Predictors of graft and patient survival in subjects undergoing transplantation for hepatitis C virus infection. Liver Transpl 2010; 16: 536-537.
23. Demirci MS, Toz H, Yilmaz F, Ertilav M, Asci G, Ozkahya M, et al. Risk factors and consequences of post-transplant diabetes mellitus. Clin Transplant 2010; 24: E170-E177.
24. Kuo HT, Sampaio MS, Ye X, Reddy P, Martin P, Bunnapradist S,. Risk factors for new-onset diabetes mellitus in adult liver transplant recipients, an analysis of the Organ Procurement and Transplant Network/United Network for Organ Sharing database. Transplantation 2010; 89: 1134-1140.
25. Gelley F, Zadori G, Firneisz G, Wagner L, Fehervári I, Gerlei Z, et al. Relationship between hepatitis C virus recurrence and de novo diabetes after liver transplantation: the Hungarian experience. Transplant Proc 2011; 43: 1281-1282.
26. Foxton MR, Quaglia A, Muiesan P, Heneghan MA, Portmann B, Norris S, et al. The impact of diabetes mellitus on fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2006; 6: 1922-1929. (Pubitemid 44024965)
27. Cotler SJ, Kallwitz E, TenCate V, Bhushan A, Berkes J, Benedetti E, et al. Diabetes and hepatic oxidative damage are associated with hepatitis C progression after liver transplantation. Transplantation 2007; 84: 587-591. (Pubitemid 47429038)
28. Veldt BJ, Poterucha JJ, Watt KD, Wiesner RH, Hay JE, Rosen CB, et al. Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant 2009; 9: 1406-1413.
29. Pagadala M, Dasarathy S, Eghtesad B, McCullough AJ,. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009; 15: 1662-1670.
30. Watt KDS,. Obesity and metabolic complications of liver transplantation. Liver Transpl 2010; 16 (suppl 2): S65-S71.
31. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z,. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
32. Hübscher SG,. What is the long-term outcome of the liver allograft? J Hepatol 2011; 55: 702-717.
33. Watt KD, Charlton MR,. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199-206.
34. Abraham SC, Poterucha JJ, Rosen CB, Demetris AJ, Krasinskas AM,. Histologic abnormalities are common in protocol liver allograft biopsies from patients with normal liver function tests. Am J Surg Pathol 2008; 32: 965-973.
35. Mells G, Mann C, Hubscher S, Neuberger J,. Late protocol liver biopsies in the liver allograft: a neglected investigation? Liver Transpl 2009; 15: 931-938.
36. Dumortier J, Giostra E, Belbouab S, Morard I, Guillaud O, Spahr L, et al. Non-alcoholic fatty liver disease in liver transplant recipients: another story of "seed and soil". Am J Gastroenterol 2010; 105: 613-620.
37. Mells G, Neuberger J,. Protocol liver allograft biopsies. Transplantation 2008; 85: 1686-1692.
38. Berenguer M, Rayõn JM, Prieto M, Aguilera V, Nicolás D, Ortiz V, et al. Are posttransplantation protocol liver biopsies useful in the long term? Liver Transpl 2001; 7: 790-796. (Pubitemid 32851300)
39. Sebagh M, Rifai K, Féray C, Yilmaz F, Falissard B, Roche B, et al. All liver recipients benefit from the protocol 10-year liver biopsies. Hepatology 2003; 37: 1293-1301. (Pubitemid 36667308)
40. Firpi RJ, Abdelmalek MF, Soldevila-Pico C, Cabrera R, Shuster JJ, Theriaque D, et al. One-year protocol liver biopsy can stratify fibrosis progression in liver transplant recipients with recurrent hepatitis C infection. Liver Transpl 2004; 10: 1240-1247. (Pubitemid 39406077)
41. Gallegos-Orozco JF, Yosephy A, Noble B, Aqel BA, Byrne TJ, Carey EJ, et al. Natural history of post-liver transplantation hepatitis C: a review of factors that may influence its course. Liver Transpl 2009; 15: 1872-1881.
42. Manousou P, Dhillon AP, Isgro G, Calvaruso V, Luong TV, Tsochatzis E, et al. Digital image analysis of liver collagen predicts clinical outcome of recurrent hepatitis C virus 1 year after liver transplantation. Liver Transpl 2011; 17: 178-188.
43. Cholongitas E, Tsochatzis E, Goulis J, Burroughs AK,. Noninvasive tests for evaluation of fibrosis in HCV recurrence after liver transplantation: a systematic review. Transpl Int 2010; 23: 861-870.
44. Beckebaum S, Iacob S, Klein CG, Dechêne A, Varghese J, Baba HA, et al. Assessment of allograft fibrosis by transient elastography and noninvasive biomarker scoring systems in liver transplant patients. Transplantation 2010; 89: 983-993.
45. Carriõn JA, Fernández-Varo G, Bruguera M, García-Pagán JC, García-Valdecasas JC, Pérez-Del- Pulgar S, et al. Serum fibrosis markers identify patients with mild and progressive hepatitis C recurrence after liver transplantation. Gastroenterology 2010; 138: 147-158.
46. Carriõn JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X,. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34.
47. Berenguer M, Prieto M, Palau A, Rayõn JM, Carrasco D, Juan FS, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003; 9: 228-235. (Pubitemid 36322323)
48. Verran D, Kusyk T, Painter D, Fisher J, Koorey D, Strasser S, et al. Clinical experience gained from the use of 120 steatotic donor livers for orthotopic liver transplantation. Liver Transpl 2003; 9: 500-505. (Pubitemid 36621720)
49. Briceño J, Ciria R, Pleguezuelo M, de la Mata M, Muntané J, Naranjo A, et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl 2009; 15: 37-48.
50. Botha JF, Thompson E, Gilroy R, Grant WJ, Mukherjee S, Lyden ER, et al. Mild donor liver steatosis has no impact on hepatitis C virus fibrosis progression following liver transplantation. Liver Int 2007; 27: 758-763. (Pubitemid 47062042)
51. Burra P, Loreno M, Russo FP, Germani G, Galligioni A, Senzolo M, et al. Donor livers with steatosis are safe to use in hepatitis C virus-positive recipients. Liver Transpl 2009; 15: 619-628.
52. Pelletier SJ, Iezzoni JC, Crabtree TD, Hahn YS, Sawyer RG, Pruett TL,. Prediction of liver allograft fibrosis after transplantation for hepatitis C virus: persistent elevation of serum transaminase levels versus necroinflammatory activity. Liver Transpl 2000; 6: 44-53. (Pubitemid 30123367)
53. Gordon FD, Pomfret EA, Pomposelli JJ, Lewis WD, Jenkins RL, Khettry U,. Severe steatosis as the initial histologic manifestation of recurrent hepatitis C genotype 3. Hum Pathol 2004; 35: 636-638. (Pubitemid 38656952)
54. El-Badry AM, Breitenstein S, Jochum W, Washington K, Paradis V, Rubbia-Brandt L, et al. Assessment of hepatic steatosis by expert pathologists: the end of a gold standard. Ann Surg 2009; 250: 691-697.
55. Leandro G, Mangia A, Hui J, Fabris P, Rubbia-Brandt L, Colloredo G, et al.; for HCV Meta-Analysis (on) Individual Patients' Data Study Group. Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data. Gastroenterology 2006; 130: 1636-1642.
56. Testino G, Borro P,. Hepatitis C recurrence: influence of serum cholesterol levels and liver steatosis on antiviral therapy. Hepatology 2011; 53: 1409-1410.